Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer biologic profile and clinicopathologic features

Breast

Volumn 22, Issue 1, 2013, Pages 89-95

  Laliotis, Aggelos ^a   Vrekoussis, Thomas ^b   Kafousi, Maria ^a   Sanidas, Elias ^a   Askoxilakis, John ^a   Melissas, John ^a   Mavroudis, Dimitrios ^a   Castanas, Elias ^a   Stathopoulos, Efstathios N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast cancer; Cyclin D1; Immunohistochemistry; PElk 1

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; TRANSCRIPTION FACTOR ELK 1;

ADVERSE OUTCOME; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIXED TUMOR; MOLECULAR PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; TUMOR VOLUME;

EID: 84871713481     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.09.013     Document Type: Article

References (43)

1. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
2. Kampa M., Pelekanou V., Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids 2008, 73(9-10):953-960.
3. Booy E.P., Henson E.S., Gibson S.B. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011, 30(20):2367-2378.
4. Treeck O., Diedrich K., Ortmann O. The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 2003, 39(9):1302-1309.
5. Ronda A.C., Buitrago C., Colicheo A., de Boland A.R., Roldán E., Boland R. Activation of MAPKs by 1alpha,25(OH)2-Vitamin D3 and 17beta-estradiol in skeletal muscle cells leads to phosphorylation of Elk-1 and CREB transcription factors. J Steroid Biochem Mol Biol 2007, 103(3-5):462-466.
6. Holloway J.N., Murthy S., El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Mol Endocrinol 2004, 18(6):1396-1410.
7. Marampon F., Ciccarelli C., Zani B.M. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006, 5:5-31.
8. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006, 4(Suppl. 1):S1-26.
9. Yip C.H., Pathy N.B., Uiterwaal C.S., Taib N.A., Tan G.H., Mun K.S., et al. Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases. Breast 2011, 20(Suppl. 2):S60-S64.
10. McCarty K.S., Miller L.S., Cox E.B., Konrath J., McCarty K.S. Estrogen receptor analysis. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109(8):716-721.
11. Bonnefoi H., Diebold-Berger S., Therasse P., Hamilton A., van de Vijver M., MacGrogan G., et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?. Ann Oncol 2003, 14(3):406-413.
12. Shin H.S., Lee H.J., Nishida M., Lee M.S., Tamura R., Yamashita S., et al. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells. Circ Res 2003, 93:302-310.
13. Schmitt J.M., Abell E., Wagner A., Davare M.A. ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells. Mol Cell Biochem 2010, 335(1-2):155-171.
14. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the south of Switzerland. Ann Oncol 2009, 20(4):628-635.
15. Yang X.R., Sherman M.E., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443.
16. Onitilo A.A., Engel J.M., Greenlee R.T. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1-2):4-13.
17. Whitmarsh A.J., Shore P., Sharrocks A.D., Davis R.J. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995, 269(5222):403-407.
18. Yang S.H., Sharrocks A.D., Whitmarsh A.J. Transcriptional regulation by the MAP kinase signaling cascades. Gene 2003, 320:3-21.
19. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. J Cell Biochem 2004, 91(5):896-903.
20. Hill C.S., Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 1995, 80(2):199-211.
21. Price M.A., Rogers A.E., Treisman R. Comparative analysis of the ternary complex factors Elk-1, SAP-1a and SAP-2 (ERP/NET). EMBO J 1995, 14(11):2589-2601.
22. Wyrzykowska P., Stalińska K., Wawro M., Kochan J., Kasza A. Epidermal growth factor regulates PAI-1 expression via activation of the transcription factor Elk-1. Biochim Biophys Acta 2010, 1799(9):616-621.
23. Fujii S., Tokita K., Wada N., Ito K., Yamauchi C., Ito Y., et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011, 30(39):4118-4128.
24. Cancer genome atlas-. http://tcga-data.nci.nih.gov/tcga/.
25. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14(5):518-527.
26. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563.
27. Glück S., Ross J.S., Royce M., McKenna E.F., Perou C.M., Avisar E., et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2012, 132(3):781-791.
28. Amin M.A., Volpert O.V., Woods J.M., Kumar P., Harlow L.A., Koch A.E. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003, 93(4):321-329.
29. Hipskind R.A., Baccarini M., Nordheim A. Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo. Mol Cell Biol 1994 Sep, 14(9):6219-6231.
30. Hill C.S., Treisman R. Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. EMBO J 1995, 14(20):5037-5047.
31. Rao V.N., Reddy E.S. Delta elk-1, a variant of elk-1, fails to interact with the serum response factor and binds to DNA with modulated specificity. Cancer Res 1993, 53(2):215-220.
32. Shao N., Chai Y., Cui J.Q., Wang N., Aysola K., Reddy E.S., et al. Induction of apoptosis by Elk-1 and deltaElk-1 proteins. Oncogene 1998, 17(4):527-532.
33. Chai Y., Chipitsyna G., Cui J., Liao B., Liu S., Aysola K., et al. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene 2001, 20:1357-1367.
34. Sutherland R.L., Musgrove E.A. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004, 9(1):95-104.
35. Mahmoodzadeh S., Dworatzek E., Fritschka S., Pham T.H., Regitz-Zagrosek V. 17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovasc Res 2010, 85(4):719-728.
36. Roy P.G., Thompson A.M. Cyclin D1 and breast cancer. Breast 2006, 15(6):718-727.
37. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996, 16(12):6917-6925.
38. Song R.X., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002, 16(1):116-127.
39. Hennessy B.A., Harvey B.J., Healy V. 17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells. Mol Cell Endocrinol 2005, 229(1-2):39-47.
40. Pelekanou V., Kampa M., Kafousi M., Dambaki K., Darivianaki K., Vrekoussis T., et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 2007 Oct, 16(10):2016-2023.
41. Pelekanou V., Notas G., Sanidas E., Tsapis A., Castanas E., Kampa M. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. Mol Oncol 2010, 4(2):135-149.
42. Kampa M., Notas G., Pelekanou V., Troullinaki M., Andrianaki M., Azariadis K., et al. Early membrane initiated transcriptional effects of estrogens in breast cancer cells: first pharmacological evidence for a novel membrane estrogen receptor element (ERx). Steroids 2012 Aug, 77(10):959-967.
43. Duan R., Xie W., Burghardt R.C., Safe S. Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J Biol Chem 2001, 276(15):11590-11598.